Research programme: isoform specific antibodies - IsomAb
Latest Information Update: 16 Dec 2022
At a glance
- Originator IsomAb
- Class Antibodies; Vascular disorder therapies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atherosclerosis
Most Recent Events
- 16 Dec 2022 Preclinical trials in Atherosclerosis in United Kingdom (Parenteral) before December 2022 (IsomAb website, December 2022)
- 16 Dec 2022 IsomAb plans to take its first product into the clinic by 2026